

Time of Meeting: 8:00 a.m.

Place of Meeting: Holiday Inn Georgetown, 2101 Wisconsin Avenue, Washington, D.C. 20007.

Agenda: Discussion of Future Initiatives with Emphasis on Stored Samples for Genetic Research.

Contact Person: Susan E. Old, Ph.D., NHLBI/DHVD, Two Rockledge Center, 6701 Rockledge Drive, Rm. 9150, MSC 7940, Bethesda, Maryland 20892, (301) 435-0560.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: December 30, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.
[FR Doc. 97-326 Filed 1-7-97; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

Name of SEP: Tuberculosis Academic Award Review.

Date: January 28, 1997.

Time: 9:00 a.m.

Place: Chevy Chase Holiday Inn, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Louise P. Corman, Ph.D., Two Rockledge Center, Room 7180, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0270.

Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: Reference Laboratory to Evaluate Therapies for Sickle Cell Disease (Telephone Conference Call).

Date: February 26, 1997.

Time: 1:30 p.m.

Place: Rockledge Building II, Room 7214, 6701 Rockledge Drive, Bethesda, Maryland 20892.

Contact Person: Diane M. Reid, M.D., Two Rockledge Center, Room 7182, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0277.

Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: Molecular Genetics of Coagulation Disorders.

Date: February 26-27, 1997.

Time: 7:30 p.m.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.

Contact Person: Louis M. Ouellette, Ph.D., Two Rockledge Center, Room 7216, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0310.

Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: Hepatic Gene Therapy for Hemophilia B.

Date: February 27-28, 1997.

Time: 7:30 p.m.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.

Contact Person: Louis M. Ouellette, Ph.D., Two Rockledge Center, Room 7216, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0310.

Purpose/Agenda: To review and evaluate grant applications.

These meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: December 30, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.
[FR Doc. 97-328 Filed 1-7-97; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meetings:

Name of SEP: Radio Frequency Coils for High Field MRI (Telephone Conference Call).

Date: January 22, 1997.

Time: 2:00 p.m.

Place: Rockledge Building Two, Room 7214, 6701 Rockledge Drive, Bethesda, Maryland.

Contact Person: Ivan Baines, Ph.D., Two Rockledge Center, Room 7184, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0277.

Purpose/Agenda: To review and evaluate contract proposals.

Name of SEP: ECG Monitoring in MRI to Detect Cardiac Ischemia (Telephone Conference Call).

Date: January 22, 1997.

Time: 2:45 p.m.

Place: Rockledge Building Two, Room 7214, 6701 Rockledge Drive, Bethesda, Maryland.

Contact Person: Ivan Baines, Ph.D., Two Rockledge Center, Room 7184, 6701

Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0277.

Purpose/Agenda: To review and evaluate contract proposals.

These meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to these meetings due to the urgent need to meet timing limitations imposed by the contract review and funding cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: December 30, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.
[FR Doc. 97-329 Filed 1-7-97; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Neurological Disorders and Stroke; Notice of Meetings

Pursuant to Public Law 92-463, notice is hereby given of meetings of the National Institute of Neurological Disorders and Stroke (NINDS).

The National Advisory Neurological Disorders and Stroke Council and its subcommittee meetings will be open to the public as indicated below. Attendance by the public will be limited to space available.

The meetings will be closed to the public as indicated below in accordance with the provisions set forth in sections 552(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Public Law 92-463, for the review, discussion and evaluation of individual grant applications. These applications and discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Summaries of meetings, rosters of committee members, and other information pertaining to the meetings can be obtained from the Executive